Literature DB >> 8876217

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.

Y Noguchi1, A Jungbluth, E C Richards, L J Old.   

Abstract

Interleukin (IL)-12 has strong antitumor activity in transplantable tumor systems in the mouse. The present study was designed to determine whether tumor induction by 3-methylcholanthrene (3-MC), a carcinogenic hydrocarbon, can be inhibited by IL-12. BALB/cBy mice were injected subcutaneously with 25 micrograms or 100 micrograms of 3-MC and treated with 100 ng, 10 ng, or 1 ng of IL-12 for 5 days a week for 18 weeks, with a schedule of 3 weeks on and 1 week off. In mice injected with 25 micrograms of 3-MC, treatment with 100 ng of IL-12 delayed tumor appearance and reduced tumor incidence. Tumor appearance was also delayed in mice injected with 100 micrograms of 3-MC and treated with 100 ng of IL-12, but the final tumor incidence was the same as in non-IL-12-treated mice. In contrast to the characteristically round, hard, well-circumscribed, and protruding tumor induced by 3-MC, a percentage of tumors induced in IL-12-treated mice had atypical characteristics: flat, soft, and invasive. Atypical tumors had a longer latent period and were more frequently seen in mice injected with 100 micrograms of 3-MC and treated with 100 ng of IL-12. Interferon gamma, IL-10, and tumor necrosis factor could be induced throughout the treatment period by IL-12, indicating that repeated injections of IL-12 do not induce a state of tachyphylaxis. High production of interferon gamma by CD8 T cells and a TH2-->TH1 or TH0 shift in the cytokine secretion profile of CD4 T cells were also seen in the IL-12-treated mice. IL-12 provides a powerful new way to explore the defensive role of the immune system in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876217      PMCID: PMC38138          DOI: 10.1073/pnas.93.21.11798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  The role of the reticuloendothelial system in the host reaction to neoplasia.

Authors:  L J OLD; B BENACERRAF; D A CLARKE; E A CARSWELL; E STOCKERT
Journal:  Cancer Res       Date:  1961-10       Impact factor: 12.701

Review 2.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

3.  Immunodepression and malignancy.

Authors:  O Stutman
Journal:  Adv Cancer Res       Date:  1975       Impact factor: 6.242

4.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.

Authors:  M A Basombrío
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

5.  Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

Authors:  R T Gazzinelli; S Hieny; T A Wynn; S Wolf; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.

Authors:  Y Noguchi; E C Richards; Y T Chen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

7.  Effects of IL-12 on the response and susceptibility to experimental viral infections.

Authors:  J S Orange; S F Wolf; C A Biron
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

8.  Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma.

Authors:  C S Tripp; M K Gately; J Hakimi; P Ling; E R Unanue
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

9.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

Authors:  M J Brunda; L Luistro; R R Warrier; R B Wright; B R Hubbard; M Murphy; S F Wolf; M K Gately
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

10.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.

Authors:  R J North; I Bursuker
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  33 in total

1.  IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

Authors:  Maya Eisenring; Johannes vom Berg; Glen Kristiansen; Elisabeth Saller; Burkhard Becher
Journal:  Nat Immunol       Date:  2010-10-10       Impact factor: 25.606

Review 2.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Contribution of IL12A and IL12B polymorphisms to the risk of cervical cancer.

Authors:  Andrzej Roszak; Adrianna Mostowska; Anna Sowińska; Margarita Lianeri; Pawel P Jagodziński
Journal:  Pathol Oncol Res       Date:  2012-05-22       Impact factor: 3.201

4.  Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma.

Authors:  Biswajit Chakraborty; Ramkrishna Pal; Mohammed Ali; Leichombam Mohindro Singh; Dewan Shahidur Rahman; Sujit Kumar Ghosh; Mahuya Sengupta
Journal:  Cell Mol Immunol       Date:  2015-05-04       Impact factor: 11.530

5.  Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse.

Authors:  Akimitsu Takagi; Haruo Ikemura; Takeshi Matsuzaki; Mikiko Sato; Koji Nomoto; Masami Morotomi; Teruo Yokokura
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

Review 6.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

Review 7.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Authors:  Yoshihiro Hayakawa; Stefania Rovero; Guido Forni; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

9.  Interleukin-12B rs3212227 polymorphism and cancer risk: a meta-analysis.

Authors:  Huilong Chen; Sheng Cheng; Jianmiao Wang; Chao Cao; Hansvin Bunjhoo; Weining Xiong; Yongjian Xu
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

Review 10.  A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas.

Authors:  T H Schreiber; E R Podack
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.